| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.0041 | 1 |